Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases

被引:144
作者
Baek, Seung Joon [1 ]
Eling, Thomas [2 ]
机构
[1] Seoul Natl Univ, Coll Vet Med, Lab Signal Transduct, Bldg 81 Rm 413,1 Gwanak Ro, Seoul 08826, South Korea
[2] NIEHS, NIH, 111 TW Alexander Dr Bldg 101 F-095, Res Triangle Pk, NC 27709 USA
基金
新加坡国家研究基金会;
关键词
Growth differentiation factor 15; Non-steroidal anti-inflammatory drug activated gene-1; Obesity; Cancer prevention; GFRAL receptor complex; Appetite suppression; Energy metabolism; Aging; Survival; MACROPHAGE INHIBITORY CYTOKINE-1; BETA SUPERFAMILY MEMBER; DRUG-ACTIVATED GENE-1; CANCER CELLS; RISK STRATIFICATION; INDUCED EXPRESSION; WEIGHT-LOSS; DNA-DAMAGE; RECEPTOR; NAG-1;
D O I
10.1016/j.pharmthera.2019.02.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Growth Differentiation Factor 15 (GDF15), also known as NSAID activated gene-1 (NAG-1), is associated with a large number of biological processes and diseases, including cancer and obesity. GDF15 is synthesized as proGDF15, is dimerized, and is cleaved and secreted into the circulation as a mature dimer GDF15. Both the intracellular GDF15 and the circulating mature GDF15 are implicated in biological processes, such as energy homeostasis and body weight regulation. Although there have been many studies on GDF15, GFRAL, a member of the glial-derived neurotropic factor receptor a family, has only been recently identified as a receptor for mature GDF15. In this review, we focused on cancer and energy homeostasis along with obesity and body weight, and the effect of the identification of the GDF15 receptor in these investigations. In addition, the therapeutic potential of GDF15 as a pharmacological agent in obesity and other metabolic diseases was discussed. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:46 / 58
页数:13
相关论文
共 111 条
[1]   Growth Differentiation Factor-15 Deficiency Augments Inflammatory Response and Exacerbates Septic Heart and Renal Injury Induced by Lipopolysaccharide [J].
Abulizi, Palida ;
Loganathan, Neruja ;
Zhao, Duo ;
Mele, Tina ;
Zhang, Yixin ;
Zwiep, Terry ;
Liu, Kexiang ;
Zheng, Xiufen .
SCIENTIFIC REPORTS, 2017, 7
[2]  
Ackermann K., 2018, BIORXIV
[3]   GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective [J].
Adela, Ramu ;
Banerjee, Sanjay K. .
JOURNAL OF DIABETES RESEARCH, 2015, 2015
[4]   Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia [J].
Baek, Seung Joon ;
Okazaki, Ryuji ;
Lee, Seong-Ho ;
Martinez, Jeanelle ;
Kim, Jong-Sik ;
Yamaguchi, Kiyoshi ;
Mishina, Yuji ;
Martin, David W. ;
Shoieb, Ahmed ;
Mcentee, Michael F. ;
Eling, Thomas E. .
GASTROENTEROLOGY, 2006, 131 (05) :1553-1560
[5]   Changes in gene expression contribute to cancer prevention by COX inhibitors [J].
Baek, SJ ;
Eling, TE .
PROGRESS IN LIPID RESEARCH, 2006, 45 (01) :1-16
[6]   Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells [J].
Baek, SJ ;
Kim, JS ;
Jackson, FR ;
Eling, TE ;
McEntee, MF ;
Lee, SH .
CARCINOGENESIS, 2004, 25 (12) :2425-2432
[7]   Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1 [J].
Baek, SJ ;
Kim, JS ;
Nixon, JB ;
DiAugustine, RP ;
Eling, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (08) :6883-6892
[8]   Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ -: A novel mechanism for its anti-tumorigenic activity [J].
Baek, SJ ;
Wilson, LC ;
Hsi, LC ;
Eling, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :5845-5853
[9]   Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction of NSAID-activated gene [J].
Baek, SJ ;
Wilson, LC ;
Lee, CH ;
Eling, TE .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (03) :1126-1131
[10]   Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53 [J].
Baek, SJ ;
Wilson, LC ;
Eling, TE .
CARCINOGENESIS, 2002, 23 (03) :425-434